Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML. Ikoma Y, Nakamura N, Kaneda Y, Takamori H, et al. Leukemia 2025;39:1362-1367.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ikoma Y, Nakamura N, Kaneda Y, Takamori H, et al. Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML. Leukemia 2025;39:1362-1367.
PMID: 40259101